These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36411577)

  • 1. Bioactives from Marine Organisms and their Potential Role as Matrix Metalloproteinase Inhibitors.
    Thomas NV; Monica Diyya AS; Kim SK; Faraj KA; Ghafoor DD; Qian ZJ; Tigabu BM
    Curr Pharm Des; 2022; 28(41):3351-3362. PubMed ID: 36411577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metalloproteinase inhibitors: status and scope from marine organisms.
    Thomas NV; Kim SK
    Biochem Res Int; 2010; 2010():845975. PubMed ID: 21197102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential matrix metalloproteinase inhibitors from edible marine algae: a review.
    Thomas NV; Manivasagan P; Kim SK
    Environ Toxicol Pharmacol; 2014 May; 37(3):1090-100. PubMed ID: 24780533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fucoidans from marine algae as potential matrix metalloproteinase inhibitors.
    Thomas NV; Kim SK
    Adv Food Nutr Res; 2014; 72():177-193. PubMed ID: 25081083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.
    Zhang C; Kim SK
    Mar Drugs; 2009 Mar; 7(2):71-84. PubMed ID: 19597572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation.
    Gentile E; Liuzzi GM
    Drug Discov Today; 2017 Feb; 22(2):299-313. PubMed ID: 27697495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phlorotannins and fucoidans from marine macroalgae as matrix metalloproteinase inhibitory substances and their possible application as medicinal foods.
    Kim SK; Thomas NV; Li X
    Adv Food Nutr Res; 2011; 64():129-41. PubMed ID: 22054943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
    Shi Y; Ma X; Fang G; Tian X; Ge C
    NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
    Winer A; Adams S; Mignatti P
    Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase enzymes and their naturally derived inhibitors: novel targets in photocarcinoma therapy.
    Gupta A; Kaur CD; Jangdey M; Saraf S
    Ageing Res Rev; 2014 Jan; 13():65-74. PubMed ID: 24355347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
    Lin H; Xu P; Huang M
    Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxamic acids as matrix metalloproteinase inhibitors.
    Verma RP
    Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The past, present and future perspectives of matrix metalloproteinase inhibitors.
    Li K; Tay FR; Yiu CKY
    Pharmacol Ther; 2020 Mar; 207():107465. PubMed ID: 31863819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?
    Koutroulis I; Zarros A; Theocharis S
    Expert Opin Ther Targets; 2008 Dec; 12(12):1577-86. PubMed ID: 19007324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
    Li X; Wu JF
    Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seesaw of matrix metalloproteinases (MMPs).
    Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
    J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.